🇺🇸 AZTREONAM LYSINE in United States

9,624 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cystic Fibrosis — 2,806 reports (29.16%)
  2. Off Label Use — 1,403 reports (14.58%)
  3. Pneumonia — 1,212 reports (12.59%)
  4. Death — 1,079 reports (11.21%)
  5. Infection — 787 reports (8.18%)
  6. Lung Disorder — 547 reports (5.68%)
  7. Lung Transplant — 503 reports (5.23%)
  8. Cystic Fibrosis Respiratory Infection Suppression — 446 reports (4.63%)
  9. Condition Aggravated — 435 reports (4.52%)
  10. Dyspnoea — 406 reports (4.22%)

Source database →

AZTREONAM LYSINE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is AZTREONAM LYSINE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for AZTREONAM LYSINE in United States?

Marketing authorisation holder not available in our data.